

LISTING OF THE CLAIMS

1 – 53 (Cancelled).

54. (**Currently amended**) A cosmetic treatment method for stabilizing, increasing or restoring collagen, comprising the steps of identifying a subject suffering from a collagen deficient condition, selected from the group consisting of wrinkles, strias, atony of the skin, or sun exposure to the skin, and topically administering a pharmaceutical composition comprising [[an]] a steroidal aromatase inhibitor to said subject in an amount sufficient to alleviate at least one symptom of said collagen deficient condition.

55. (Cancelled)

56. (Previously Presented) The method of claim 54, wherein the pharmaceutical composition further comprises a therapeutically effective amount of an anti-estrogen.

57. (Previously Presented) The method of claim 54, wherein the pharmaceutical composition further comprises a therapeutically effective amount of a 5-alpha-reductase inhibitor.

58. (**Currently amended**) The method of claim [[54]] 56, wherein administration of said pharmaceutical composition locally inhibits aromatase activity or locally inhibits the production and/or effect of estrogens.

59. (**Currently amended**) The method of claim [[54]] 57, wherein administration of said pharmaceutical composition locally inhibits the production and/or the effect of dihydrotestosterone.

60. (**Currently amended**) The method of claim [[54]] 57, wherein administration of said pharmaceutical composition locally inhibits aromatase activity and 5-alpha-reductase activity.

61. (Previously Presented) The method of claim 54, wherein the aromatase inhibitor is a steroid compound.

62. (Previously Presented) The method of claim 54, wherein the aromatase inhibitor is a sterol.

63. (Previously Presented) The method of claim 62, wherein the sterol is isolated from soya glycines.

64. (Previously Presented) The method of claim 63, wherein the sterol isolated from soya glycines is treated by oxidation.

65. (Previously Presented) The method of claim 54, wherein the pharmaceutical composition comprises between about 0.001 and about 5% by weight of said aromatase inhibitor.

66. (Previously Presented) The method of claim 54, wherein the pharmaceutical composition is formulated for topical administration as an ointment, a cream, a gel, an oil, an emulsion or a lotion.

67. (Previously Presented) The method of claim 54, further comprising stabilizing, increasing or restoring collagen in the skin of the subject.

68. (Previously Presented) A method for the cosmetic treatment of wrinkles, strias or atony of the skin, comprising the steps of identifying a subject suffering from wrinkles, strias or atony of the skin and topically administering a pharmaceutical composition comprising an aromatase inhibitor to said subject in an amount sufficient to alleviate at least one symptom of said wrinkles, strias or atony.

69. (Previously Presented) A method for the amelioration of sun exposure to the skin, the method comprising the steps of identifying a subject suffering from sun exposure to the skin and topically administering a pharmaceutical composition comprising an aromatase inhibitor to said subject in an amount sufficient to alleviate at least one symptom of sun exposure to the skin.

70. (Withdrawn) A method for the treatment of injured ligaments, tendons, or other collagen containing parts of the body, the method comprising the steps of identifying a subject suffering from an injured ligament, tendon, or other collagen containing part of the body and topically administering a pharmaceutical composition comprising an aromatase inhibitor to said subject in an amount sufficient to treat at least one symptom of said injured ligament, tendon, or other collagen containing part.

71. (Withdrawn) A method for influencing the rate of hair growth, the method comprising the steps of identifying a subject in need of controlling hair growth and topically administering a pharmaceutical composition comprising an aromatase inhibitor to said subject in an amount sufficient to influence the rate of hair growth.